|
1
|
d’Amore F, Brincker H, Grønbaek K, et al:
Non-Hodgkin’s lymphoma of the gastrointestinal tract: a
population-based analysis of incidence, geographic distribution,
clinicopathologic presentation features, and prognosis. Danish
Lymphoma Study Group. J Clin Oncol. 12:1673–1684. 1994.
|
|
2
|
Psyrri A, Papageorgiou S and Economopoulos
T: Primary extranodal lymphomas of stomach: clinical presentation,
diagnostic pitfalls and management. Ann Oncol. 19:1992–1999.
2008.
|
|
3
|
Coiffier B and Salles G: Does surgery
belong to medical history for gastric lymphomas? Ann Oncol.
8:419–421. 1997.
|
|
4
|
Raderer M, Chott A, Drach J, et al:
Chemotherapy for management of localised high-grade gastric B-cell
lymphoma: how much is necessary? Ann Oncol. 13:1094–1098. 2002.
|
|
5
|
Tanaka T, Shimada K, Yamamoto K, et al:
Retrospective analysis of primary gastric diffuse large B cell
lymphoma in the rituximab era: a multicenter study of 95 patients
in Japan. Ann Hematol. 91:383–390. 2012.
|
|
6
|
Zhang J, Li G, Yang H, Liu X and Cao J:
Rituximab in treatment of primary gastric diffuse large B-cell
lymphoma. Leuk Lymphoma. 53:2175–2181. 2012.
|
|
7
|
Hughes RA, Britton T and Richards M:
Effects of lymphoma on the peripheral nervous system. J R Soc Med.
87:526–530. 1994.
|
|
8
|
Recht LD: Neurologic complications of
systemic lymphoma. Neurol Clin. 9:1001–1015. 1991.
|
|
9
|
Law IP, Dick FR, Blom J and Bergevin PR:
Involvement of the central nervous system in non-Hodgkin’s
lymphoma. Cancer. 36:225–231. 1975.
|
|
10
|
Levitt LJ, Dawson DM, Rosenthal DS and
Moloney WC: CNS involvement in the non-Hodgkin’s lymphomas. Cancer.
45:545–552. 1980.
|
|
11
|
MacKintosh FR, Colby TV, Podolsky WJ, et
al: Central nervous system involvement in non-Hodgkin’s lymphoma:
an analysis of 105 cases. Cancer. 49:586–595. 1982.
|
|
12
|
Woodruff MM and Edlow JA: Evaluation of
third nerve palsy in the emergency department. J Emerg Med.
35:239–246. 2008.
|
|
13
|
Bruce BB, Biousse V and Newman NJ: Third
nerve palsies. Semin Neurol. 27:257–268. 2007.
|
|
14
|
Feugier P, Virion JM, Tilly H, et al:
Incidence and risk factors for central nervous system occurrence in
elderly patients with diffuse large-B-cell lymphoma: influence of
rituximab. Ann Oncol. 15:129–133. 2004.
|
|
15
|
Kumar A, Vanderplas A, LaCasce AS, et al:
Lack of benefit of central nervous system prophylaxis for diffuse
large B-cell lymphoma in the rituximab era: findings from a large
national database. Cancer. 118:2944–2951. 2012.
|
|
16
|
Tomita N, Yokoyama M, Yamamoto W, et al:
Central nervous system event in patients with diffuse large B-cell
lymphoma in the rituximab era. Cancer Sci. 103:245–251. 2012.
|
|
17
|
van Besien K, Gisselbrecht C, Pfreundschuh
M and Zucca E: Secondary lymphomas of the central nervous system:
risk, prophylaxis and treatment. Leuk Lymphoma. 49:52–58. 2008.
|
|
18
|
Kim SJ, Oh SY, Kim JS, et al: Secondary
central nervous system (CNS) involvement in patients with diffuse
large B-cell lymphoma: a therapeutic dilemma. Ann Hematol.
90:539–546. 2011.
|
|
19
|
Jacobson DM: Relative pupil-sparing third
nerve palsy: etiology and clinical variables predictive of a mass.
Neurology. 56:797–798. 2001.
|
|
20
|
Sato H, Hashimoto T, Yoneda S, Hirabayashi
K, Oguchi K and Higuchi K: Lymphoma as a cause of isolated
oculomotor nerve palsy. J Clin Neurosci. 18:1256–1258. 2011.
|
